EBS Emergent BioSolutions Inc
Emergent BioSolutions Inc (EBS) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.75 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -22.9% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Emergent BioSolutions Inc
Emergent BioSolutions Inc is a specialty biopharmaceutical company operating in two divisions: Biodefense and Biosciences. Its products include BioThrax, BAT, Anthrasil, VIGIV, RSDL, NuThrax, PreviThrax and GC-072.
Sector
Healthcare
Industry
Biotechnology